Skip to main content
Weiter zur Homepage der Europäischen Kommission (öffnet in neuem Fenster)
Deutsch de
CORDIS - Forschungsergebnisse der EU
CORDIS

Spatiotemporal Mapping of Immune Cell Behavior in Glioblastoma

Ziel

Immune cells, particularly cytotoxic T lymphocytes, are highly motile capable of infiltrating and eliminating tumors—a feature driving the recent revolution of immunotherapies. Yet a common barrier is the failure of T cells to infiltrate tumors, with local peritumoral and perivascular arrest as a key hurdle. Efforts to overcome this, such as decades of targeting of major tumor-supportive cytokines have yielded limited breakthroughs. A likely reason is methodological bias: most studies profile bulk tissues at single endpoints, detecting only sustained, widespread signals while overlooking the transient, localized interactions that may drive T-cell arrest.
I propose to develop spatially and temporally resolved transcriptomic technology to map immune cell interactions and behavior over time, and apply it to study immune dysfunction in glioblastoma (GBM), a lethal brain tumor. I recently developed Zman-seq, the first in vivo single-cell method to capture immune cell state transitions over time and their driving signals. Zman-seq revealed that immune reprogramming occurs rapidly within just a day after infiltration. To resolve the early local interactions driving this, we will combine spatial data with Zman-seq, and measure T-cell motility as a functional readout. First, to pinpoint the early niches, I will combine Zman-seq timestamps with spatial transcriptomics and describe how immune cells occupy cellular niches over time. Next, to study T-cell behavior within these niches, I will directly visualize T-cell motility via intravital microscopy and register in vivo tracks to ex vivo spatial transcriptomics, creating a new approach—VideoTranscriptomics. Applied in a GBM model, this will reveal the sequence of niches immune cells traverse, and pinpoint early, targetable checkpoints that drive T-cell arrest and immunotherapy resistance.

Wissenschaftliches Gebiet (EuroSciVoc)

Dieses Projekt wurde noch nicht bei EuroSciVoc klassifiziert.
Schlagen Sie die Wissenschaftsbereiche vor, die Ihrer Einschätzung nach besonders relevant sind, und helfen Sie uns, unseren Klassifizierungsdienst zu verbessern.

Schlüsselbegriffe

Programm/Programme

Thema/Themen

Finanzierungsplan

HORIZON-ERC - HORIZON ERC Grants

Alle im Rahmen dieses Finanzierungsinstruments finanzierten Projekte anzeigen

Aufforderung zur Vorschlagseinreichung

(öffnet in neuem Fenster) ERC-2026-STG

Alle im Rahmen dieser Aufforderung zur Einreichung von Vorschlägen finanzierten Projekte anzeigen

Gastgebende Einrichtung

DEUTSCHES KREBSFORSCHUNGSZENTRUM HEIDELBERG
Netto-EU-Beitrag
€ 1 484 173,00
Adresse
IM NEUENHEIMER FELD 280
69120 Heidelberg
Deutschland
Region
Baden-Württemberg Karlsruhe Heidelberg, Stadtkreis
Aktivitätstyp
Research Organisations
Links
Gesamtkosten
€ 1 484 173,75

Begünstigte (1)